Tickernomics

10y

Historical Returns*:

SPY

27.80%

AQST

83.00%

SPY

32.66%

-6.63%

AQST

SPY

108.59%

-33.88%

AQST

SPY

302.52%

AQST

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

332.45

260.15

0.84

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-9.45

5.64

-7.32

-8.01

0.00

-10.51

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-61.22

100.00

-41.79

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

16.1696

-66.86

-89.96

3.22

Other Earnings and Cash Flow Stats:

Aquestive Therapeutics Inc. ( AQST ) Net Income TTM ($MM) is -35.19

Aquestive Therapeutics Inc. ( AQST ) Operating Income TTM ($MM) is -21.10

Aquestive Therapeutics Inc. ( AQST ) Owners' Earnings Annual ($MM) is -6.42

Aquestive Therapeutics Inc. ( AQST ) Current Price to Owners' Earnings ratio is -20.36

Aquestive Therapeutics Inc. ( AQST ) EBITDA TTM ($MM) is -20.06

Aquestive Therapeutics Inc. ( AQST ) EBITDA Margin is -41.79%

Capital Allocation:

Aquestive Therapeutics Inc. ( AQST ) has paid 0.00 dividends per share and bought back -26.403321 million shares in the past 12 months

Aquestive Therapeutics Inc. ( AQST ) has reduced its debt by 39.813 million USD in the last 12 months

Capital Structure:

Aquestive Therapeutics Inc. ( AQST ) Interest-bearing Debt ($MM) as of last quarter is 5

Aquestive Therapeutics Inc. ( AQST ) Annual Working Capital Investments ($MM) are 2

Aquestive Therapeutics Inc. ( AQST ) Book Value ($MM) as of last quarter is -46

Aquestive Therapeutics Inc. ( AQST ) Debt/Capital as of last quarter is -13%

Other Balance Sheet Stats:

Aquestive Therapeutics Inc. ( AQST ) has 77 million in cash on hand as of last quarter

Aquestive Therapeutics Inc. ( AQST ) has 15 million of liabilities due within 12 months, and long term debt 30 as of last quarter

Aquestive Therapeutics Inc. ( AQST ) has 91 common shares outstanding as of last quarter

Aquestive Therapeutics Inc. ( AQST ) has 0 million USD of preferred stock value

Academic Scores:

Aquestive Therapeutics Inc. ( AQST ) Altman Z-Score is -2.46 as of last quarter

Aquestive Therapeutics Inc. ( AQST ) Piotroski Score is 4.00 as of last quarter

Corporate Governance:

Aquestive Therapeutics Inc. ( AQST ) largest shareholder is Marshall Wace Asset Management Ltd owning 288884 shares at 1.06 ($MM) value

Jung Cassie(an insider) Sold 44 shares of Aquestive Therapeutics Inc. ( AQST ) for the amount of $214.06 on 2024-11-26

5.01% of Aquestive Therapeutics Inc. ( AQST ) is held by insiders, and 48.09% is held by institutions

Aquestive Therapeutics Inc. ( AQST ) went public on 2018-07-25

About Aquestive Therapeutics Inc. ( AQST ) :

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.